MDT

95.83

-0.32%↓

136.93

+0.54%↑

VEEV

220.3

-1.26%↓

HQY

91.46

-0.05%↓

PHR.US

16.42

-2.84%↓

MDT

95.83

-0.32%↓

136.93

+0.54%↑

VEEV

220.3

-1.26%↓

HQY

91.46

-0.05%↓

PHR.US

16.42

-2.84%↓

MDT

95.83

-0.32%↓

136.93

+0.54%↑

VEEV

220.3

-1.26%↓

HQY

91.46

-0.05%↓

PHR.US

16.42

-2.84%↓

MDT

95.83

-0.32%↓

136.93

+0.54%↑

VEEV

220.3

-1.26%↓

HQY

91.46

-0.05%↓

PHR.US

16.42

-2.84%↓

MDT

95.83

-0.32%↓

136.93

+0.54%↑

VEEV

220.3

-1.26%↓

HQY

91.46

-0.05%↓

PHR.US

16.42

-2.84%↓

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

43.93 -1.99

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

43.76

Максимум

44.91

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+22.62% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	196M 3.4B
Предишно отваряне	45.92
Предишно затваряне	43.93

Настроения в новините

By Acuity

25%

75%

40 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.12.2025 г., 22:20 ч. UTC

Значими двигатели на пазара

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31.12.2025 г., 17:31 ч. UTC

Значими двигатели на пазара

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31.12.2025 г., 16:30 ч. UTC

Значими двигатели на пазара

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31.12.2025 г., 15:19 ч. UTC

Значими двигатели на пазара

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31.12.2025 г., 15:17 ч. UTC

Значими двигатели на пазара

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31.12.2025 г., 14:37 ч. UTC

Значими двигатели на пазара

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

1.01.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Rises Amid Geopolitical Risks -- Market Talk

1.01.2026 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

1.01.2026 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Sold Stake in JV to Tata Steel

1.01.2026 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

1.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.01.2026 г., 09:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

31.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

31.12.2025 г., 21:13 ч. UTC

Придобивния, сливания и поглъщания

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31.12.2025 г., 20:40 ч. UTC

Пазарно говорене

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31.12.2025 г., 20:22 ч. UTC

Пазарно говорене

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31.12.2025 г., 19:50 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31.12.2025 г., 19:31 ч. UTC

Пазарно говорене

Precious Metals Cap Off Record Runs -- Market Talk

31.12.2025 г., 18:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

31.12.2025 г., 18:50 ч. UTC

Пазарно говорене

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31.12.2025 г., 17:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31.12.2025 г., 17:16 ч. UTC

Значими двигатели на пазара

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

31.12.2025 г., 17:00 ч. UTC

Придобивния, сливания и поглъщания

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31.12.2025 г., 15:57 ч. UTC

Придобивния, сливания и поглъщания

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31.12.2025 г., 15:54 ч. UTC

Пазарно говорене

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31.12.2025 г., 15:02 ч. UTC

Значими двигатели на пазара

Nike Shares Rise After CEO Hill Buys $1M of Shares

31.12.2025 г., 14:40 ч. UTC

Придобивния, сливания и поглъщания

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31.12.2025 г., 14:20 ч. UTC

Пазарно говорене

Crude Futures On Track to End the Year With Losses -- Market Talk

31.12.2025 г., 13:46 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

22.62% нагоре

12-месечна прогноза

Среден 54.96 USD 22.62%

Висок 65 USD

Нисък 44 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

40 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.